A Randomized, Prospective, Placebo-Controlled Clinical Trial of a Novel Zinc-Monocysteine Compound in Age-Related Macular Degeneration

Newsome, David A.

doi:10.1080/02713680802178437

Cited by 54 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age differences observed in the NC subgroup, and for the overall study sample, are in general agreement with previous observations on the relationship between PSRT measures and age. 34,41,42 In addition, the mean PSRT of the NC group observed herein (7.03 ± 2.41 seconds for PSRT 3) is longer than that previously observed in a younger (mean age, 35 years) normal cohort using the same device (5.11 ± 1.51 seconds for PSRT 3). 30 In the absence of any age-defined normative values for the device, such age dependency is of clinical relevance and suggests that eye health practitioners should interpret individual PSRT measures with caution, except where evidence exists of intereye asymmetry or elongation of PSRT over time on repeated measures.…”

Section: Discussionmentioning

confidence: 46%

“…40 Importantly, PSRT deficits have been observed in asymptomatic subjects where visual acuity is relatively preserved, indicating that a suitably designed test might provide an effective indicator of early disease or disease progression. 41 This study is the first to explore the effect of diabetes including nonproliferative DR, on PSRT in comparison to NCs, and to evaluate the repeatability of PSRT measures among naive subjects with and without nonproliferative DR. The trend toward shorter PSRT measures on repeat testing is in general agreement with previous observations among younger participants, although the trends were not statistically significant in this study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Suitability and Repeatability of a Photostress Recovery Test Device, the Macular Degeneration Detector (Mdd-2), for Diabetes and Diabetic Retinopathy Assessment

Loughman

Ratzlaff

Foerg³

et al. 2014

Retina

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 46%

Section: Discussionmentioning

confidence: 99%

Suitability and Repeatability of a Photostress Recovery Test Device, the Macular Degeneration Detector (Mdd-2), for Diabetes and Diabetic Retinopathy Assessment

Loughman

Ratzlaff

Foerg³

et al. 2014

Retina

View full text Add to dashboard Cite

“…6 j 3987 studies that were included, four were prospective cohort studies, two were retrospective cohort studies, and four were RCTs (one RCT had an additional publication). [13][14][15][16][17][18][19][20][21][22] The study specifics including study design and subject characteristics are summarized in Table 1 and the overall results are summarized in Table 2.…”

Section: Search Resultsmentioning

confidence: 99%

A Systematic Review on Zinc for the Prevention and Treatment of Age-Related Macular Degeneration

Vishwanathan

Chung

Johnson

2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Citation: Vishwanathan R, Chung M, Johnson EJ. A systematic review on zinc for the prevention and treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54:3985-3998. DOI:10.1167/ iovs.12-11552 PURPOSE. The objective of this systematic review was to examine the evidence on zinc intake from foods and supplements in the primary prevention and treatment of AMD.METHODS. Randomized controlled trials (RCTs), prospective cohort, retrospective cohort, and case-control studies that investigated zinc intake from foods and/or supplements, and AMD in men and women with a mean age of 50 years or older were included. Medline and Cochrane Central were searched from inception to February 2012 and November 2012, respectively. Data extraction and quality appraisal were done on all eligible studies.RESULTS. Ten studies were included: four RCTs, four prospective cohort, and two retrospective cohort studies. Age-related Eye Disease Study (AREDS) showed zinc treatment to significantly reduce the risk of progression to advanced AMD. The risk of visual acuity loss was of similar magnitude, but not statistically significant. Two RCTs reported statistically significant increases in visual acuity in early AMD patients and one RCT showed no effect of zinc treatment on visual acuity in advanced AMD patients. Results from six cohort studies on associations between zinc intake and incidence of AMD were inconsistent.CONCLUSIONS. Current evidence on zinc intake for the prevention of AMD is inconclusive. Based on the strength of AREDS, we can conclude that zinc treatment may be effective in preventing progression to advanced AMD. Zinc supplementation alone may not be sufficient to produce clinically meaningful changes in visual acuity.

show abstract

“…The effect and tolerance of zinc supplementation was also investigated [62,63], and it appeared to improve macular function in patients with dry AMD [63]. The beneficial effect of zinc supplements was also reported in a recent analysis conducted by Beatty et al in a trial that focused on carotenoids with coantioxidants in age-related maculopathy.…”

Section: Zincmentioning

confidence: 97%

Review of nutrient actions on age-related macular degeneration

Zampatti¹,

Ricci²,

Cusumano³

et al. 2014

Nutrition Research

View full text Add to dashboard Cite

The actions of nutrients and related compounds on age-related macular degeneration however, this does not appear to be particularly beneficial in healthy people. Furthermore, some supplements or nutrients have demonstrated discordant effects on AMD in some studies. Since intake of dietary supplements, as well as exposure to damaging environmental factors, is largely dependent on population habits (including dietary practices) and geographical localization, an overall healthy diet appears to be the best strategy in reducing the risk of developing AMD. As of now, the precise mechanism of action of certain nutrients in AMD prevention remains unclear. Thus, future studies are required to examine the effects that nutrients have on AMD and to determine which factors are most strongly correlated with reducing the risk of AMD or preventing its progression.

show abstract

A Randomized, Prospective, Placebo-Controlled Clinical Trial of a Novel Zinc-Monocysteine Compound in Age-Related Macular Degeneration

Abstract: ZMC 25 mg twice daily was well tolerated and was associated with improved macular function in comparison to a placebo in persons with dry AMD.

Cited by 54 publications

References 33 publications

Suitability and Repeatability of a Photostress Recovery Test Device, the Macular Degeneration Detector (Mdd-2), for Diabetes and Diabetic Retinopathy Assessment

Suitability and Repeatability of a Photostress Recovery Test Device, the Macular Degeneration Detector (Mdd-2), for Diabetes and Diabetic Retinopathy Assessment

A Systematic Review on Zinc for the Prevention and Treatment of Age-Related Macular Degeneration

Review of nutrient actions on age-related macular degeneration

Contact Info

Product

Resources

About